Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 3
1993 2
1994 1
1995 2
1996 7
1997 7
1998 4
1999 8
2000 17
2001 11
2002 7
2003 8
2004 12
2005 15
2006 12
2007 15
2008 20
2009 12
2010 13
2011 24
2012 24
2013 18
2014 19
2015 30
2016 30
2017 25
2018 23
2019 23
2020 23
2021 16
2022 10
2023 4
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

392 results

Results by year

Filters applied: . Clear all
Page 1
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME; SU2C/PCF West Coast Prostate Cancer Dream Team; Quigley DA, Feng FY, Chi KN, Wyatt AW. Herberts C, et al. Among authors: gleave me. Nature. 2022 Aug;608(7921):199-208. doi: 10.1038/s41586-022-04975-9. Epub 2022 Jul 20. Nature. 2022. PMID: 35859180
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, Wang L, Gleave ME, Wang Y, Shi L, Huang H. He Y, et al. Among authors: gleave me. Nat Commun. 2021 Mar 9;12(1):1521. doi: 10.1038/s41467-021-21860-7. Nat Commun. 2021. PMID: 33750801 Free PMC article.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Among authors: gleave me. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Beltran H, et al. Among authors: gleave me. Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130. Cancer Discov. 2011. PMID: 22389870 Free PMC article.
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: gleave me. J Urol. 2021 Feb;205(2):339-340. doi: 10.1097/JU.0000000000001444. Epub 2020 Nov 6. J Urol. 2021. PMID: 33155864 No abstract available.
Towards precision oncology in advanced prostate cancer.
Ku SY, Gleave ME, Beltran H. Ku SY, et al. Among authors: gleave me. Nat Rev Urol. 2019 Nov;16(11):645-654. doi: 10.1038/s41585-019-0237-8. Epub 2019 Oct 7. Nat Rev Urol. 2019. PMID: 31591549 Free PMC article. Review.
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: gleave me. J Urol. 2020 Apr;203(4):733. doi: 10.1097/JU.0000000000000621.02. Epub 2020 Jan 17. J Urol. 2020. PMID: 31951502 No abstract available.
PARP inhibition in castration-resistant prostate cancer.
Nappi L, Gleave ME. Nappi L, et al. Among authors: gleave me. Future Oncol. 2016 Mar;12(5):577-80. doi: 10.2217/fon.16.1. Epub 2016 Jan 21. Future Oncol. 2016. PMID: 26792387 Free article. No abstract available.
Reply.
Ting A, Gleave ME, Hsiang YN. Ting A, et al. Among authors: gleave me. J Vasc Surg. 2000 Mar;31(3):625-6. J Vasc Surg. 2000. PMID: 10709085 No abstract available.
392 results